报价延迟最少15分钟:2026/04/15 09:41 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.53 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.80/-1.13
|
|
企业价值
343.86M
|
| 资产负债 |
|
每股账面净值
0.28
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
40.52M
|
|
每股收益
0.25
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology. |
